The aim of this Phase Ⅰ/Ⅱ study is to evaluate the safety and efficacy of dendritic cells (DCs) vaccine combined with cytokine-induced killer (CIK) cells in patients with AML. Experimental recombinant adenovirus-transfected DCs, which engineered to express MUC1 and Survivin are used for DCs-based immunotherapy. Based on the results of our previously performed preclinical study with DCs vaccine combined with CIK cells, the investigators plan to perform the clinical trial.
Consistent with the diagnosis of AML
Age≥18 years at time of consent
KPS(Karnofsky Performance Scale) ≥70
Patient's written informed consent
Serious dysfunction of vital organs(heart, liver or kidney)
Received organ transplantation
Patients with other malignancies or brain metastases
History of autoimmune diseases
Single group
Adenovirus-transfected DC + CIK
Biological/VaccineAdenovirus-transfected autologous DC vaccine plus CIK cells
PFS/OS
Number of participants with adverse events
Click on the lead sponsor to view all of their trials.
